Financial news, mergers and acquisitions, partnerships, and alliances.
The financing will go toward efforts by the German firm to bring its point-of-care screening system for drug-resistant bacteria to hospitals.
The Pro-Seq technology links molecules prior to sequencing to enable detection of low-frequency variants, and could be complementary to Boreal's OnTarget technology.
Tempus and Rush will work together to rapidly collect and analyze important biospecimens to fuel cancer research.
The newly announced tie-up wants to alleviate the shortage of bioinformaticists by taking over data management and storage for genomics researchers.
